Masahiro Hirakawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Masahiro Hirakawa has a total of 46 co-authors. Here are the top co-authors by number of shared publications:
- Junji Kato
Department of Medical Oncology, Sapporo Medical University School of Medicine, Sapporo, Japan
8 shared publications - Yasushi Sato
Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
7 shared publications - Masayoshi Kobune
Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
6 shared publications - Kohichi Takada
Sapporo Medical University School of Medicine, Hokkaido Prefecture, Japan
5 shared publications Rishu Takimoto
Department of Medical Oncology and Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
5 shared publications- Satoshi Iyama
Department of Hematology, Sapporo Medical University School of Medicine, Sapporo, Japan
5 shared publications
Latest Publications
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 123
A phase I/II study of definitive chemoradiotherapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for advanced esophageal cancer.
123 Background: Definitive chemoradiotherapy is one of the options for advanced esophageal cancer (AEC). However, AEC patient survival remains unsatisfactory. To investigate a regimen of definitive chemoradiotherapy that exerts good local control of AEC, we performed a phase I/II study to assess the safety and efficacy of triple-drug chemoradiotherapy with docetaxel, 5-fluorouracil, and nedaplatin (DNF-R) that has less adverse events than cisplatin. Methods: Eligible patients had stage II-IVA AEC. Patients received 2 cycles of docetaxel (20, 30, or 40 mg/m2 for dose levels 1, 2, or 3) and nedaplatin (50 mg/m2) on days 1 and 8, and a continuous infusion of 5-fluorouracil (400 mg/m2/day) on days 1-5 and 8-12, with concurrent radiotherapy (on days 1-5, 8-12, and 15-19, total 60 Gy) every 5 weeks. After DNF-R, patients received at least 2 more cycles of DNF. The recommended dose (RD) was determined with a 3 + 3 design. Results: Thirty-one patients were enrolled from July 2010 to April 2013. In the phase I study, the dose-limiting toxicity (DLT) was grade 4 neutropenia, which was observed in all 3 patients at dose level 2.Thus, the RD schedule was level 1. In the phase II study, the 25 eligibles had a median age of 64 (range 56-78; male/female: 21/4), with PS0/1/2 of 13/10/2 and cStage II/III/IVA of 6/10/9. Grade 3/4 acute toxicity included neutropenia (46%), leukopenia (43%), febrile neutropenia (11%), thrombocytopenia (18%), esophagitis (18%), and nausea (11%) during CRT. Grade3/4 late radiotoxicity included 2 cases of esophagostenosis (7%), but they improved by dilatation. Of the 28 patients treated at the RD level 1, including 3 patients of the RD phase I portion, all of them showed response including 23 (82%) CR and 5 PR. The protocol completion rate was 96.4% (27/28). No treatment-related death was observed. The median PFS (1-year PFS: 67.6% and 3-year PFS: 44.8%) and OS were 21 months and 33.2 months, respectively. The 3-year survival rate was 62.5%. Conclusions: DNF-R showed good tolerability and achieved a high CR rate, suggesting that it is a potentially effective therapeutic regimen for AEC. Clinical trial information: UMIN000005446.
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 123
A phase I/II study of definitive chemoradiotherapy with docetaxel, nedaplatin, and 5-fluorouracil (DNF-R) for advanced esophageal cancer.
123 Background: Definitive chemoradiotherapy is one of the options for advanced esophageal cancer (AEC). However, AEC patient survival remains unsatisfactory. To investigate a regimen of definitive chemoradiotherapy that exerts good local control of AEC, we performed a phase I/II study to assess the safety and efficacy of triple-drug chemoradiotherapy with docetaxel, 5-fluorouracil, and nedaplatin (DNF-R) that has less adverse events than cisplatin. Methods: Eligible patients had stage II-IVA AEC. Patients received 2 cycles of docetaxel (20, 30, or 40 mg/m2 for dose levels 1, 2, or 3) and nedaplatin (50 mg/m2) on days 1 and 8, and a continuous infusion of 5-fluorouracil (400 mg/m2/day) on days 1-5 and 8-12, with concurrent radiotherapy (on days 1-5, 8-12, and 15-19, total 60 Gy) every 5 weeks. After DNF-R, patients received at least 2 more cycles of DNF. The recommended dose (RD) was determined with a 3 + 3 design. Results: Thirty-one patients were enrolled from July 2010 to April 2013. In the phase I study, the dose-limiting toxicity (DLT) was grade 4 neutropenia, which was observed in all 3 patients at dose level 2.Thus, the RD schedule was level 1. In the phase II study, the 25 eligibles had a median age of 64 (range 56-78; male/female: 21/4), with PS0/1/2 of 13/10/2 and cStage II/III/IVA of 6/10/9. Grade 3/4 acute toxicity included neutropenia (46%), leukopenia (43%), febrile neutropenia (11%), thrombocytopenia (18%), esophagitis (18%), and nausea (11%) during CRT. Grade3/4 late radiotoxicity included 2 cases of esophagostenosis (7%), but they improved by dilatation. Of the 28 patients treated at the RD level 1, including 3 patients of the RD phase I portion, all of them showed response including 23 (82%) CR and 5 PR. The protocol completion rate was 96.4% (27/28). No treatment-related death was observed. The median PFS (1-year PFS: 67.6% and 3-year PFS: 44.8%) and OS were 21 months and 33.2 months, respectively. The 3-year survival rate was 62.5%. Conclusions: DNF-R showed good tolerability and achieved a high CR rate, suggesting that it is a potentially effective therapeutic regimen for AEC. Clinical trial information: UMIN000005446.
- 20 January 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (3) , 612
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer.
612 Background: In a recent study by Loupakis, F. et al. (ASCO-GI 2013), a FOLFOXIRI and bevacizumab regimen showed promising activity and conversion rate in patients (pts) with metastatic colorectal cancer (mCRC). In order to evaluate a treatment regimen that was easier to administer, we conducted a dose-escalation study to determine the recommended dose (RD) of irinotecan (IRI) in combination with oxaliplatin and capecitabine and bevacizumab (XELOXIRI/bev) in pts with mCRC. Methods: Pts were eligible if they had mCRC (liver and/or other metastases), ECOG PS 0-1, were either negative or heterozygous for UGT1A1*6 or UGT1A1*28 and were not pretreated for metastatic disease. Treatment consisted of oxaliplatin (100 mg/m2 day 1), capecitabine (1700 mg/m2/day from day 2 to 15), IRI (100,120,150 mg/m2 for dose levels 1, 2, or 3, day 1) and bev (7.5 mg/kg, day 1), repeated every 3 weeks. The dose of IRI was escalated if dose limiting toxicities (DLT) were absent in the first three pts per cohort, or if 2, which is the maximum dosage approved for use in Japan. Results: 12 pts (F/M: 4/8, median age: 58 years, PS 0/1: 11/1) received a median of 6 cycles of therapy (range 2-12). The DLT was grade 4 neutropenia, which was observed in 1 of 6 pts at dose level 2. MTD was not reached at dose level 3. Therefore, the RD of IRI was defined as 150 mg/m2. Most common grade ≥ 3 toxicities were neutropenia (58.3%), anemia (16.6 %), diarrhea (8.3%), and febrile neutropenia (8.3 %). The response rate was 83.3%(95% CI 60-89), including 1 CR, 9 PRs. The disease control rate was 100%(95% CI 80-100). At a median follow-up of 8 months, median PFS was 15 months and median OS was not yet reached. Conclusions: XELOXIRI/bev is a feasible regimen; neutropenia was the DLT; recommended dose of IRI is 150 mg/m². The observed response rate of 83.3% is very promising and warrants further investigation. Clinical trial information: UMIN000005440.
- 20 January 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (3) , 612
A dose-escalation study of oxaliplatin/capecitabine/irinotecan (XELOXIRI) and bevacizumab (bev) as a first-line therapy for patients with metastatic colorectal cancer.
612 Background: In a recent study by Loupakis, F. et al. (ASCO-GI 2013), a FOLFOXIRI and bevacizumab regimen showed promising activity and conversion rate in patients (pts) with metastatic colorectal cancer (mCRC). In order to evaluate a treatment regimen that was easier to administer, we conducted a dose-escalation study to determine the recommended dose (RD) of irinotecan (IRI) in combination with oxaliplatin and capecitabine and bevacizumab (XELOXIRI/bev) in pts with mCRC. Methods: Pts were eligible if they had mCRC (liver and/or other metastases), ECOG PS 0-1, were either negative or heterozygous for UGT1A1*6 or UGT1A1*28 and were not pretreated for metastatic disease. Treatment consisted of oxaliplatin (100 mg/m2 day 1), capecitabine (1700 mg/m2/day from day 2 to 15), IRI (100,120,150 mg/m2 for dose levels 1, 2, or 3, day 1) and bev (7.5 mg/kg, day 1), repeated every 3 weeks. The dose of IRI was escalated if dose limiting toxicities (DLT) were absent in the first three pts per cohort, or if 2, which is the maximum dosage approved for use in Japan. Results: 12 pts (F/M: 4/8, median age: 58 years, PS 0/1: 11/1) received a median of 6 cycles of therapy (range 2-12). The DLT was grade 4 neutropenia, which was observed in 1 of 6 pts at dose level 2. MTD was not reached at dose level 3. Therefore, the RD of IRI was defined as 150 mg/m2. Most common grade ≥ 3 toxicities were neutropenia (58.3%), anemia (16.6 %), diarrhea (8.3%), and febrile neutropenia (8.3 %). The response rate was 83.3%(95% CI 60-89), including 1 CR, 9 PRs. The disease control rate was 100%(95% CI 80-100). At a median follow-up of 8 months, median PFS was 15 months and median OS was not yet reached. Conclusions: XELOXIRI/bev is a feasible regimen; neutropenia was the DLT; recommended dose of IRI is 150 mg/m². The observed response rate of 83.3% is very promising and warrants further investigation. Clinical trial information: UMIN000005440.
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB213
Sa1592 Improved Visualization of Small Bowel Lesions by Capsule Endoscopy Using Flexible Spectral Imaging Color Enhancement (FICE) System
- 1 April 2012
- Published by Elsevier in Gastrointestinal Endoscopy
- Vol. 75 (4) , AB213
Sa1592 Improved Visualization of Small Bowel Lesions by Capsule Endoscopy Using Flexible Spectral Imaging Color Enhancement (FICE) System
- Open Access
- 1 January 2012
- Published by Japan Society of Hepatology in Kanzo
- Vol. 53 (10) , 615-623
A case of double cholangiolocellular carcinoma and hepatocellular carcinoma complicated with non-alcoholic steatohepatitis
症例は68歳女性.非アルコール性脂肪性肝炎(NASH)として外来通院中であったが,腹部MRI検査で多発肝腫瘍を認め,精査加療目的にて入院となった.腫瘍はS3に22 mmの結節性病変を,またS1とS4およびS6にも小結節性病変を認めた.切除標本においてS3病変は境界明瞭で被膜形成のない白色充実性腫瘍で,免疫染色ではCK7,CK19,EMA陽性,HepPar1陰性であり細胆管細胞癌の所見であった.一方S4の病変はdysplastic noduleであった.S1およびS6病変は画像検査上肝細胞癌の診断にてRFAを施行された.NASHを背景肝として発症した細胆管細胞癌と肝細胞癌の合併は稀であり文献的考察を加えて報告する.
- 1 January 2012
- Published by Japan Society of Hepatology in Kanzo
- Vol. 53 (10) , 615-623
Open AccessA case of double cholangiolocellular carcinoma and hepatocellular carcinoma complicated with non-alcoholic steatohepatitis
症例は68歳女性.非アルコール性脂肪性肝炎(NASH)として外来通院中であったが,腹部MRI検査で多発肝腫瘍を認め,精査加療目的にて入院となった.腫瘍はS3に22 mmの結節性病変を,またS1とS4およびS6にも小結節性病変を認めた.切除標本においてS3病変は境界明瞭で被膜形成のない白色充実性腫瘍で,免疫染色ではCK7,CK19,EMA陽性,HepPar1陰性であり細胆管細胞癌の所見であった.一方S4の病変はdysplastic noduleであった.S1およびS6病変は画像検査上肝細胞癌の診断にてRFAを施行された.NASHを背景肝として発症した細胆管細胞癌と肝細胞癌の合併は稀であり文献的考察を加えて報告する.
- 1 February 2011
- Vol. 108 (2) , 231-7
[Tuberculous pleuritis with onset of refractory pleural effusion after chemoradiotherapy for esophageal cancer].
A 75-year-old man received chemoradiotherapy (CRT) for stage IVa esophageal cancer and complete response (CR) was obtained. However, he was referred to our department for recurrence in an area of esophagus not included in the previously irradiated field. Left pleural effusion increased after admission. Tuberculous pleuritis was eventually diagnosed by thoracoscopic pleural biopsy. It is necessary to accurately diagnose the cause of pleural effusion after CRT, because treatment strategies greatly depend on it. It is also necessary to consider the possible onset of tuberculous pleuritis, in particular, in patients with a history of tuberculosis infection.
- 1 February 2011
- Vol. 108 (2) , 231-7
[Tuberculous pleuritis with onset of refractory pleural effusion after chemoradiotherapy for esophageal cancer].
A 75-year-old man received chemoradiotherapy (CRT) for stage IVa esophageal cancer and complete response (CR) was obtained. However, he was referred to our department for recurrence in an area of esophagus not included in the previously irradiated field. Left pleural effusion increased after admission. Tuberculous pleuritis was eventually diagnosed by thoracoscopic pleural biopsy. It is necessary to accurately diagnose the cause of pleural effusion after CRT, because treatment strategies greatly depend on it. It is also necessary to consider the possible onset of tuberculous pleuritis, in particular, in patients with a history of tuberculosis infection.
- 1 September 2007
- Vol. 34 (9) , 1467-71
[Fifth-line chemotherapy for metastatic gastric cancer--a case responding to modified FOLFOX 6].
According to the National Comprehensive Cancer Network (NCCN) clinical practice guideline for gastric cancer (2006, the first edition), 5-FU/Leucovorin (LV), 5-FU-based, cisplatin (CDDP)-based, oxaliplatin (L-OHP)-based, taxane-based, and irinotecan (CPT-11)-based, ECF are recommended. We used modified FOLFOX 6 (mFOLFOX 6) for pretreatment, that is oxaliplatin-based chemotherapy, for a patient who had received 5-FU-based, CDDPbased, taxane-based, and CPT-11-based treatment for an unresectable gastric cancer case responding to mFOLFOX 6. A 73-year-old male admitted to our hospital for treatment of advanced gastric cancer was diagnosed to be inoperable. A combination chemotherapy docetaxel and CDDP and S-1 as first-line treatment, CPT-11 and CDDP as second-line treatment, weekly paclitaxel treatment as third-line treatment, and MTX and 5-FU as fourth-line treatment were performed. He had progressed after 5-FU-based, CDDP-based, taxane-based, and CPT-11-based chemotherapy. There are no effective approved drugs for gastric cancer in Japan. Oxaliplatin was reportedly effective for metastatic gastric cancer, but it is still non-approved in Japan. After receiving an explanation of oxaliplatin-based therapy, he gave informed consent. Oxaliplatin-based therapy for this patient was then evaluated and approved under an institutional review board of Higashi Sapporo Hospital. mFOLFOX 6 used for the oxaliplatin-based therapy. After 2 courses of mFOLFOX 6, he showed a partial response. Oxaliplatin-based treatment was thought to be promising for previously CDDP-treated patients with unresectable gastric cancers.
- 1 September 2007
- Vol. 34 (9) , 1467-71
[Fifth-line chemotherapy for metastatic gastric cancer--a case responding to modified FOLFOX 6].
According to the National Comprehensive Cancer Network (NCCN) clinical practice guideline for gastric cancer (2006, the first edition), 5-FU/Leucovorin (LV), 5-FU-based, cisplatin (CDDP)-based, oxaliplatin (L-OHP)-based, taxane-based, and irinotecan (CPT-11)-based, ECF are recommended. We used modified FOLFOX 6 (mFOLFOX 6) for pretreatment, that is oxaliplatin-based chemotherapy, for a patient who had received 5-FU-based, CDDPbased, taxane-based, and CPT-11-based treatment for an unresectable gastric cancer case responding to mFOLFOX 6. A 73-year-old male admitted to our hospital for treatment of advanced gastric cancer was diagnosed to be inoperable. A combination chemotherapy docetaxel and CDDP and S-1 as first-line treatment, CPT-11 and CDDP as second-line treatment, weekly paclitaxel treatment as third-line treatment, and MTX and 5-FU as fourth-line treatment were performed. He had progressed after 5-FU-based, CDDP-based, taxane-based, and CPT-11-based chemotherapy. There are no effective approved drugs for gastric cancer in Japan. Oxaliplatin was reportedly effective for metastatic gastric cancer, but it is still non-approved in Japan. After receiving an explanation of oxaliplatin-based therapy, he gave informed consent. Oxaliplatin-based therapy for this patient was then evaluated and approved under an institutional review board of Higashi Sapporo Hospital. mFOLFOX 6 used for the oxaliplatin-based therapy. After 2 courses of mFOLFOX 6, he showed a partial response. Oxaliplatin-based treatment was thought to be promising for previously CDDP-treated patients with unresectable gastric cancers.
- 1 September 2007
- Vol. 34 (9) , 1481-4
[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].
A 70-year-old man was admitted for tranverse colon cancer with multiple liver metastases. Hepatic arterial infusion chemotherapy and systemic chemotherapy (FOLFOX 4) were conducted postoperatively. Thirteen months after the first surgery, liver metastases became resectable and hepatectomy was performed. Though multiple liver metastases were unresectable at the time of the first examination, hepatectomy was possible followed by hepatic arterial infusion chemotherapy and systemic chemotherapy.
- 1 September 2007
- Vol. 34 (9) , 1481-4
[A case of resection of synchronous multiple liver metastases from colorectal cancer after hepatic infusion chemotherapy and systemic chemotherapy].
A 70-year-old man was admitted for tranverse colon cancer with multiple liver metastases. Hepatic arterial infusion chemotherapy and systemic chemotherapy (FOLFOX 4) were conducted postoperatively. Thirteen months after the first surgery, liver metastases became resectable and hepatectomy was performed. Though multiple liver metastases were unresectable at the time of the first examination, hepatectomy was possible followed by hepatic arterial infusion chemotherapy and systemic chemotherapy.
- 1 July 2007
- Vol. 48 (7) , 554-8
[Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].
A 47-year-old woman was admitted to our hospital in December 1994 with polycythemia. The patient's red blood cell volume was 33 ml/kg and bone marrow cytology was able to rule out other myeloproliferative diseases such as chronic myelogenous leukemia, essential thrombocytosis and myelofibrosis. The patient was diagnosed as having polycythemia vera. She had undergone only phlebotomy until 1999 when the thrombocytosis appeared, subsequent to which she was treated with oral hydroxyurea. However, in March 2006, she developed upper abdominal pain and was admitted to our hospital on March 14th, 2006. Computed tomography scan revealed thromboses in the portal and superior mesenteric veins. Anticoagulation therapy delivered intravenously via the superior mesenteric vein dramatically improved her symptoms and liver function. She is currently on anticoagulation therapy in our outpatient clinic.
- 1 July 2007
- Vol. 48 (7) , 554-8
[Superior mesenteric and portal vein thrombosis in a polycythemia vera patient with JAK2 mutation].
A 47-year-old woman was admitted to our hospital in December 1994 with polycythemia. The patient's red blood cell volume was 33 ml/kg and bone marrow cytology was able to rule out other myeloproliferative diseases such as chronic myelogenous leukemia, essential thrombocytosis and myelofibrosis. The patient was diagnosed as having polycythemia vera. She had undergone only phlebotomy until 1999 when the thrombocytosis appeared, subsequent to which she was treated with oral hydroxyurea. However, in March 2006, she developed upper abdominal pain and was admitted to our hospital on March 14th, 2006. Computed tomography scan revealed thromboses in the portal and superior mesenteric veins. Anticoagulation therapy delivered intravenously via the superior mesenteric vein dramatically improved her symptoms and liver function. She is currently on anticoagulation therapy in our outpatient clinic.